A novel potent and selective kynurenine-3-hydroxylase inhibitor is descibed along a preliminary evaluation in a in vivo gerbil model of its ability to increase the kynurenine and kynurenic acid concentration in both plasma and brain. These data support the notion that kynurenine-3-hydroxylase inhibitors may have a sustained therapeutic potential in those diseases characterized by unbalance in the QUIN /KYNA branches of the kynurenine pathway.
|Number of pages||8|
|Journal||Advances in Experimental Medicine and Biology|
|Publication status||Published - 2003|
ASJC Scopus subject areas
- Biochemistry, Genetics and Molecular Biology(all)